Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAP-219 in Refractory Focal Epilepsy
NCT06377930Phase 2Completed
- Sponsor
- Rapport Therapeutics
- Start
- Oct 2024
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of RAP-219 in focal onset seizure, sponsored by Rapport Therapeutics. Primary endpoint: Change in long episode frequency during the treatment period compared to pre-treatment baseline at 5 months. Started Oct 2024; status: completed.
02
Drugs
RAP-219
03
Conditions
focal onset seizure
Beyond the preview
Go deeper on NCT06377930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06377930.